Tabomedex Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

Tabomedex General Information

Description

Operator of a novel therapeutics company intended to work on research and development of new drugs related to type 2 diabetes. The company is engaged in the development of MK2 which ameliorate insulin sensitivity and achieve the effect of controlling blood glucose level by inhibiting MK2, enabling patients to get treatment for type 2 diabetes and live a healthy life.

Contact Information

Website
www.tabomedex.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 4 Dana Road
  • Boxford, MA 01921
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • 4 Dana Road
  • Boxford, MA 01921
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Tabomedex Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition Completed Generating Revenue
3. Later Stage VC (Series A2) 03-Aug-2020 Completed Generating Revenue
2. Early Stage VC (Series A) 29-Dec-2017 $5M $5M Completed Startup
1. Accelerator/Incubator Completed Startup
To view Tabomedex’s complete valuation and funding history, request access »

Tabomedex Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A
To view Tabomedex’s complete cap table history, request access »

Tabomedex Patents

  • 18

    Total Documents Applications and Grants

  • Total Patents Families

  • 11

    Granted

  • 5

    Pending

  • Expiring in next 12 mo

Tabomedex Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022205678-A1 Fused quadracyclic compounds, compositions and uses thereof Pending 11-Jan-2021
CA-3204167-A1 Fused quadracyclic compounds, compositions and uses thereof Pending 11-Jan-2021
EP-4274833-A1 Fused quadracyclic compounds, compositions and uses thereof Pending 11-Jan-2021
EP-4274833-A4 Fused quadracyclic compounds, compositions and uses thereof Pending 11-Jan-2021
US-20240140958-A1 Fused quadracyclic compounds, compositions and uses thereof Pending 11-Jan-2021 C07D487/14
To view Tabomedex’s complete patent history, request access »

Tabomedex Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
JMCR Family Office Family Office Minority
Sprout Bioventures Venture Capital Minority
Viva BioInnovator Accelerator/Incubator Minority
Viva Biotech Corporation Minority
Viva Ventures Biotech Group Venture Capital Minority
To view Tabomedex’s complete investors history, request access »

Ready to get started?

Request a free trial

Tabomedex FAQs

  • When was Tabomedex founded?

    Tabomedex was founded in 2013.

  • Where is Tabomedex headquartered?

    Tabomedex is headquartered in Boxford, MA.

  • What industry is Tabomedex in?

    Tabomedex’s primary industry is Drug Discovery.

  • Is Tabomedex a private or public company?

    Tabomedex is a Private company.

  • What is Tabomedex’s current revenue?

    The current revenue for Tabomedex is .

  • How much funding has Tabomedex raised over time?

    Tabomedex has raised $10M.

  • Who are Tabomedex’s investors?

    JMCR Family Office, Sprout Bioventures, Viva BioInnovator, Viva Biotech, and Viva Ventures Biotech Group have invested in Tabomedex.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process